COVID-19

Chijioke Bennett, executive director of clinical development at Novavax, discusses how health care providers can increase awareness around the importance of COVID-19 vaccines.

Researchers addressed the association of COVID-19 pandemic-related school disruptions with children’s incidence of acute psychiatric emergencies.

The government said the tests will “detect current COVID-19 variants and can be used through the end of the year.”

Novavax is still awaiting FDA authorization for their protein-based COVID-19 vaccine.

Experts analyzed data from the National Center for Health Statistics on the leading causes of death in the US from the last 5 years.

The composition of the latest flu vaccine has changed. Here’s what pharmacists need to know.

Researchers aimed to address the change in trust individuals exhibited regarding US physicians and hospitals during the COVID-19 pandemic.

Recent research on COVID-19 examined cognitive loss after an infection, how pandemic restrictions impacted excess deaths, and the increase in physicians experiencing PTSD.

“If people think COVID is no big deal and decide to forgo vaccinations, they’re essentially doubling their risk of developing long COVID,” wrote investigators.

COVID-19 patients had reduced absolute granulocyte, monocyte, and lymphocyte counts at 10 months post-infection compared to noninfected individuals.

Updated vaccines are expected to be available in the coming months.

The updates follow the Advisory Committee for Immunization Practice meeting held June 26 to 28, 2024.

Test your pharmacy news knowledge with our weekly quiz.

A study found that cannabis use increased the risk of hospitalization and intensive care unit admission following a COVID-19 diagnosis.

Research presented at ASHP 2024 found that concerns around the safety of COVID-19 vaccines and the credibility of information from public health authorities were the biggest drivers of vaccine hesitancy during the COVID-19 pandemic.

The vaccine, mRNA-1083, elicited noninferior responses vs individual COVID-19 and flu vaccinations.

The SpeedySwab COVID + FLU A&B Self-Test from Watmind is intended for at-home and point-of-care use and can simultaneously detect COVID-19, influenza A, and influenza B in 15 minutes.

Researchers addressed the association between COVID-19 vaccination status and incidents of post-COVID condition.

Check out these top featured stories from Drug Topics in May 2024.

Health care providers must listen to patients who voice their experiences with post–COVID-19 condition symptoms. Only then can a clearer picture of the condition emerge for the millions of patients who have the near-invisible disease.

A recent study found that, of 423 participants who were initially low responders, 90% increased their antibody concentrations to more than 400 AU/mL.

Designs of existing wearables overlook the specific needs of vulnerable populations, hindering their widespread adoption among increasingly interested communities.

Pemivibart will act as an additional preventive option for COVID-19 among moderately-to-severely immunocompromised adult and adolescent patients, who are disproportionally impacted by the condition.

Recent research on COVID-19 vaccination shows that vaccines help fight variants, led to lower cases among children in California, and that boosters provide longer lasting protection.

Collecting smell and taste scores from individuals with and without a history of COVID-19, researchers found significantly lower scores for smell in COVID-19-diagnosed individuals.

Overall, older adults with diabetes faced a 53% higher risk of developing at least 1 functional limitation during the pandemic compared to older adults without diabetes.

A study from the Children’s Hospital of Philadelphia found that a positive PCR test was not associated with an increased risk of a new asthma diagnosis in patients ages 1 to 16.

Understanding the role of pharmacies in vaccination rates can help prepare officials for the next public health emergency.

mRNA-1283 generated a stronger immune response against both the Omicron BA.4/BA.5 and the original virus strains of SARS-CoV-2 compared with Spikevax, Moderna’s licensed COVID-19 vaccine.

Two posters presented at APhA 2024 examined how the COVID-19 pandemic impacted pharmacists and their work.